人妻无码中出美日韩综合视频|三级片黄色免费网站|亚洲久久人人A片,黄色网址|日韩在线人成视频免费|日韩女人一区二区三区|Caopeng97在线播放|国产精品视频一二三四五区|国产女上天堂三级片99|午夜高潮网站看看国产一级只|成人黄色电影免费看

Resources

Recommendation | N,N-Dimethylacetamide (DMAC)

N,N-Dimethylacetamide (DMAC or DMA), with the chemical formula CH?C(O)N(CH?)? and a molecular weight of 87.12 g·mol?¹, is a colorless, transparent, non-protonic polar solvent. It exhibits complete miscibility with water as well as a broad range of organic solvents—including ethers, ketones, alcohols, aromatic hydrocarbons (e.g., benzene), and esters—rendering it widely applicable as a reaction medium and processing solvent in synthetic chemistry and industrial manufacturing.Dimethylacetamide (DMAC) plays a multifaceted and strategically important role in biopharmaceutical process development, with well-documented applications across four key domains:1. Drug Synthesis and Intermediate Preparation DMAC serves as a high-boiling, polar aprotic solvent and, in certain cases, as a co-catalyst in the synthesis of antibiotics—including amoxicillin and cephalosporins—as well as anti-neoplastic agents. Its use enhances reaction kinetics, improves yield, and contributes to higher product purity. In organic synthesis of pharmaceutical intermediates, DMAC is particularly advantageous for constructing hydrophobic molecular scaffolds, owing to its ability to stabilize reactive intermediates and lower activation energy barriers—thereby facilitating efficient and selective transformations.2. Antibody–Drug Conjugate (ADC) Manufacturing In ADC conjugation chemistry, DMAC functions as a co-solvent to solubilize highly lipophilic cytotoxic payloads prior to coupling with monoclonal antibodies. When employed synergistically with non-ionic surfactants (e.g., polysorbates), DMAC supports micelle formation, which not only augments payload solubility but also improves coupling specificity and reaction homogeneity—critical factors for achieving consistent drug–antibody ratios (DAR) and batch-to-batch reproducibility.3. Advanced Drug Formulation Development Within solid dispersion technologies—particularly co-precipitation and solvent evaporation methods—DMAC acts as an effective solvent for both active pharmaceutical ingredients (APIs) and polymeric carriers (e.g., PVP, HPMCAS). Rapid removal of DMAC under controlled conditions enables the formation of stable amorphous solid dispersions (ASDs), thereby enhancing dissolution rate, apparent solubility, and oral bioavailability of BCS Class II and IV compounds. Additionally, DMAC’s favorable film-forming capacity and compatibility with diverse excipients render it suitable for fabricating polymeric membranes, microcapsules, and other controlled-release or targeted delivery systems.4. Biomacromolecule Processing In downstream processing of therapeutic proteins and nucleic acids, DMAC has demonstrated utility in solubilizing and stabilizing labile biomacromolecules during purification and extraction steps. It mitigates non-specific adsorption to chromatographic resins and reduces enzymatic or chemical degradation pathways. Furthermore, in select enzymatic syntheses (e.g., phosphorylation, ligation) and solid-phase oligonucleotide synthesis, DMAC provides a chemically inert, low-water-content environment that preserves reagent integrity and supports high-fidelity molecular assembly.The pharmaceutical application of N,N-dimethylacetamide (DMAC) necessitates stringent control over its purity, residual moisture, and impurity profile to ensure drug quality, safety, and process robustness. To date, neither the United States Pharmacopeia (USP) nor the Chinese Pharmacopoeia (ChP) has established monographs or official quality specifications for DMAC intended for medicinal use. Consequently, the European Pharmacopoeia (Ph. Eur.) serves as the de facto regulatory benchmark for pharmaceutical-grade DMAC globally. As a globally recognized supplier of high-quality pharmaceutical raw materials and excipients, PanReac AppliChem offers Ph. Eur.-compliant DMAC characterized by ≥99.0% assay purity, rigorously controlled residual moisture and organic impurities, and trace metal content strictly aligned with ICH Q3D elemental impurities guidelines. This comprehensive quality assurance minimizes interference with critical synthetic and conjugation reactions—particularly in sensitive biopharmaceutical processes—and enhances consistency, yield, and final product quality. The material is especially well-suited for the development and manufacturing of advanced biopharmaceuticals, including antibody–drug conjugates (ADCs).產(chǎn)品信息：CodeProductCAS No.143145N,N-Dimethylacetamide (BP, Ph. Eur.) pure, pharmagrade127-19-5633145N,N-Dimethylacetamide (BP, Ph. Eur.) pharma gradePanReac AppliChem is a European-based manufacturer of high-purity biochemical reagents and pharmaceutical raw materials with over a century of heritage. The company maintains compliance with multiple ISO quality management standards (including ISO 9001 and ISO 13485) and serves as a trusted global supplier to life science research institutions, leading contract research and manufacturing organizations (CROs/CDMOs), and major enterprises in the pharmaceutical, diagnostic, food, and cosmetic industries. As an approved long-term supplier to numerous internationally recognized cell culture medium and pharmaceutical manufacturers, PanReac AppliChem ranks among a select group of global producers capable of supplying pharmacopoeial-grade and cell-culture-grade raw materials across broad chemical portfolios. Its product portfolio encompasses cell culture–grade, pharmacopoeial-grade, biochemical-grade, and ultra-pure-grade chemicals—including amino acids, vitamins, antibiotics, salts, buffers, stabilizers, surfactants, and process-critical pharmaceutical excipients such as Tris, guanosine, adenine, sodium caprylate, DMSO, and dextran.XMJ Scientific is the exclusive distributor of PanReac AppliChem in China，providing users with comprehensive technical support and after-sales service. If you are interested in the products, please call XMJ's customer service hotline at 400-050-4006 or visit the website m.lxhmstone.com for more information. more>

Recommendation | L-Cysteine

L-Cysteine is a naturally occurring, sulfur-containing α-amino acid characterized by a highly reactive thiol (–SH) group. With a molecular formula of C?H?NO?S and a molecular weight of 121.16 g/mol, it typically appears as a colorless, crystalline solid. Owing to its selective nucleophilicity and redox-active thiol functionality, L-cysteine serves as a critical reagent in biopharmaceutical development and manufacturing.1. Protein Engineering and Site-Specific ModificationIn the development of antibody–drug conjugates (ADCs) and long-acting biopharmaceuticals, site-directed incorporation of L-cysteine—via genetic code expansion or codon reassignment—enables precise introduction of a reactive thiol group at predefined surface-exposed positions on therapeutic proteins (e.g., monoclonal antibodies). This strategy supports controlled, stoichiometric bioconjugation and is broadly applicable in two key therapeutic modalities: ① Antibody–drug conjugates: The genetically encoded thiol serves as a chemoselective conjugation handle for cytotoxic payloads, radionuclides, or other functional moieties. Relative to conventional lysine- or interchain cysteine-based random conjugation, this site-specific approach yields ADCs with enhanced structural homogeneity, improved batch-to-batch consistency, tighter control over drug-to-antibody ratio (DAR), and more favorable pharmacokinetic and pharmacodynamic profiles.② Protein half-life extension: Thiol-selective conjugation of polyethylene glycol (PEG) chains—using maleimide- or vinyl sulfone-based chemistries—confers sustained plasma exposure by reducing renal clearance and proteolytic degradation. This translates into prolonged terminal half-life, decreased dosing frequency, and improved patient compliance.2. Optimized Cell Culture ProcessIn the industrial-scale production of recombinant therapeutic proteins—including monoclonal antibodies and recombinant hormones—supplementation of L-cysteine (or its membrane-permeable precursor, N-acetylcysteine, NAC) represents a well-established strategy to enhance process performance. As the rate-limiting precursor for intracellular glutathione biosynthesis, L-cysteine plays a pivotal role in maintaining redox homeostasis. In large-scale bioreactor cultures, targeted supplementation confers three interrelated benefits:① Enhanced cellular antioxidant defense: Elevated intracellular glutathione levels mitigate oxidative stress, thereby improving viable cell density and prolonging the high-productivity phase of culture.② Suppression of apoptosis: By alleviating redox imbalance and endoplasmic reticulum (ER) stress, L-cysteine supplementation reduces caspase-mediated apoptotic signaling, extending culture duration and increasing integrated viable cell days (IVCD)—a key determinant of volumetric productivity.③ Improved co-translational and post-translational folding fidelity: For disulfide bond–dependent proteins (e.g., IgG antibodies), optimal L-cysteine availability supports a physiologically appropriate reducing environment within the ER lumen, facilitating efficient formation, isomerization, and validation of native disulfide pairings—ultimately increasing the proportion of correctly folded, biologically active product. 3. Downstream Purification and FormulationIn the downstream purification and formulation stages of recombinant protein drug production, L-cysteine frequently assumes a significant role:① Depolymerization of protein aggregates: During the purification process, proteins may form aggregates as a result of non - natural disulfide bonds. The addition of a low - concentration reducing agent (such as L - cysteine or its analogs) can gently reduce these mis - connected bonds, dissociate the aggregates into active monomers, and enhance the purification yield.② Antioxidant stabilizer in liquid formulations: In the liquid formulation of protein drugs, L - cysteine can serve as an antioxidant to safeguard proteins (especially the sulfhydryl groups at their active sites) from oxidation, thereby prolonging the shelf - life of the drugs.As a globally recognized supplier of high-purity pharmaceutical active pharmaceutical raw materials and excipients, PanReac AppliChem delivers consistently reliable, pharmacopeia-compliant L-cysteine of pharma grade—supporting robust performance across upstream processing, downstream purification, and formulation development in biologics manufacturing.CodeProductCAS No.A1425L-Cysteine (DAB) pure, pharma grade52-90-4PanReac AppliChem is a European-based manufacturer of high-purity biochemical reagents and pharmaceutical raw materials with over a century of heritage. The company maintains compliance with multiple ISO quality management standards (including ISO 9001 and ISO 13485) and serves as a trusted global supplier to life science research institutions, leading contract research and manufacturing organizations (CROs/CDMOs), and major enterprises in the pharmaceutical, diagnostic, food, and cosmetic industries. As an approved long-term supplier to numerous internationally recognized cell culture medium and pharmaceutical manufacturers, PanReac AppliChem ranks among a select group of global producers capable of supplying pharmacopoeial-grade and cell-culture-grade raw materials across broad chemical portfolios. Its product portfolio encompasses cell culture–grade, pharmacopoeial-grade, biochemical-grade, and ultra-pure-grade chemicals—including amino acids, vitamins, antibiotics, salts, buffers, stabilizers, surfactants, and process-critical pharmaceutical excipients such as Tris, guanosine, adenine, sodium caprylate, DMSO, and dextran.XMJ Scientific is the exclusive distributor of PanReac AppliChem in China，providing users with comprehensive technical support and after-sales service. If you are interested in the products, please call XMJ's customer service hotline at 400-050-4006 or visit the website m.lxhmstone.com for more information. more>

Cygnus AccuRes?—Precise Monitoring of Residual HCD Risks

In the manufacturing of biologics, residual host cell DNA (HCD) may persist, potentially introducing oncogenes or other risky genetic materials into the final drug product. To mitigate these risks, regulatory agencies have established limits for HCD residues. Depending on the cell line and dosing regimen, allowable HCD limits typically range from 10 to 100 pg per dose. Regarding HCD testing, the Chinese Pharmacopoeia (ChP) 2025, General Chapter 3407, outlines three methods: DNA probe hybridization, fluorescence staining, and quantitative PCR (qPCR). Meanwhile, USP General Chapter <509> "Residual DNA Testing" recommends probe-based DNA quantification as a validated method for testing recombinant biologics produced in E. coli or Chinese Hamster Ovary (CHO) cell lines to ensure superior sensitivity and accuracy. Throughout the production process, Quality Control (QC) personnel must evaluate DNA levels in samples that may contain other impurities and high concentrations of active pharmaceutical ingredients (API), necessitating a reliable and sensitive DNA quantification method. The 2025 edition of the ChP has introduced new HCD testing requirements for several monoclonal antibodies, including Trastuzumab for injection, Infliximab, Adalimumab, Bevacizumab, and Rituximab. It also specifies requirements for certain vaccines (e.g., inactivated Sabin strain poliovirus vaccine <50 pg/dose), explicitly mandating the use of General Chapter 3407 Method 3 (qPCR). Additionally, a new general chapter, , brings Antibody-Drug Conjugates (ADCs) under regulatory oversight, explicitly requiring the monitoring of exogenous impurities. The newly launched Cygnus AccuRes? series of DNA quantification kits is developed in accordance with ChP General Chapter 3407 Method 3 (qPCR). These kits are specifically designed for HCD testing in biologics recombinantly expressed in cell lines such as CHO, Human, Vero, and E. coli. High-concentration samples can be tested with minimal dilution, effectively lowering the Limit of Detection (LOD).Key Advantages of Cygnus AccuRes? HCD Detection Kits:Accuracy: Cygnus’s proprietary DNAextraction reagents remove components that interfere with PCR. Theprobe-based method ensures highly specific detection of target celllines/species (CHO, Human, Vero, E. coli), avoiding interferencefrom heterologous DNA. FAM-labeled nucleic acid probes are quenched byBHQ-1? prior to PCR amplification to ensure specificity. Enhanced Precision: The CleanAmp&reg;dNTPs and Hot-Start Taq DNA Polymerase system effectively reduceprimer-dimers and non-specific amplification before the PCR reactionreaches the denaturation temperature. Flexibility: Compatible with allqPCR instruments capable of detecting FAM signals, reducing the need foradditional equipment investment. All-in-One Kits: Supports theentire workflow from sample preparation to qPCR. Kits include DNAextraction reagents (tube or plate format), AccuRes? PCR Master Mix,Primer/Probe Mix, and DNA standards. Sensitivity: LODs are 0.6 fg/µL(CHO), 0.7 fg/µL (E. coli), and 3 fg/µL (Human). Workflow of Cygnus AccuRes? HCD Detection Kits 1. DNA Extraction: Cygnus utilizes a novel DNA carrier capable of recovering femtogram levels of HCD. The extraction process occurs in an environment free from protein, salt, and surfactant contamination, resulting in higher reproducibility and stability for DNA detection and amplification compared to other methods. 2. Amplification: The kits use a highly specific primer/probe system. FAM-labeled probes are quenched by BHQ-1? in every PCR cycle. The advanced CleanAmp&reg; dNTPs and Hot-Start Taq system ensure specificity, sensitivity, and stability, while allowing qPCR setup at room temperature. 3. Quantification: A standard curve is constructed using the Ct values of kit standards, calculating results as pg/10 µL of residual host cell DNA. This can be converted to ng/mL, ng/mg, or ng/dose. Based on this method, the Lower Limit of Quantification (LLOQ) is 0.6 fg/µL for CHO. Test Data Summary Accuracy and Repeatability: Two operators (A and B) tested known DNA samples twice over two days. Results were evaluated based on SD, CV, and % Recovery.Impact of DNA Degradation: Comparison of extraction and amplification between intact gDNA (Control) and CHO DNA digested with Alu1 enzyme for 30, 60, 90, and 120 minutes. The linear range of the Control and the 30-minute digested sample remained consistent.Specificity: The CHO primer/probe system maintains a wide linear range and high specificity even in the presence of exogenous DNA (e.g., various concentrations of E. coli DNA do not affect the CHO DNA standard curve).Process Samples & Drug Substance (DS): Recovery of CHO DNA was compared in samples containing 1 mg/mL of protein purified via anion or cation exchange, as well as in final drug substances.Ordering Information Product Name Catalog No. Size CHO AccuRes? DNA Quantification Kit in Tubes D1555T 1 kit CHO AccuRes? DNA Quantification Kit in Wells D1555W 1 kit CHO AccuRes? Quantitative DNA Kit D1555 1 kit E. coli AccuRes? Quantitative DNA Kit D1415 1 kit Human AccuRes? Quantitative DNA Kit D1165 1 kit Vero AccuRes? Quantitative DNA Kit D1975 1 kit NS/0 AccuRes? Quantitative DNA Kit D1225 1 kit Upcoming Products： Product Name Catalog No. Size SF9 AccuRes? Quantitative DNA Kit D1845 1 kit P. pastoris AccuRes? Quantitative DNA Kit D1145 1 kit Cygnus DNA Extraction Kits These kits are designed to be used in conjunction with the AccuRes? quantification kits. Product Name Catalog No. Size DNA Extraction Kit in Tubes D100T 1 kit DNA Extraction Kit in Wells D100W 1 kit Cygnus Technologies, LLC. Cygnus Technologies provides products and analytical methods to the biotechnology and biopharmaceutical industries aimed at accelerating R&D phases and enhancing product quality. Cygnus develops and manufactures bioprocess residual kits for detecting specific impurities across more than 50 different expression systems. As experts in high-sensitivity analytical technologies focused on immunoassay applications for biotechnology, Cygnus’s products and services have been utilized by nearly every major biopharmaceutical company for over 25 years.XMJ Scientific (Beijing) Co., Ltd. As the exclusive distributor for Cygnus in China, XMJ Scientific has established long-term and stable partnerships with numerous well-known domestic pharmaceutical companies and CRO/CMO enterprises. For years, XMJ’s products and services have helped many companies accelerate R&D, improve drug quality, purity, and safety, optimize manufacturing processes, reduce time-to-market, and lower QC costs more>

KPL BacTrace?antibacterial antibody

In recent years, foodborne pathogen contamination incidents have occurred frequently worldwide. Pathogens such as Salmonella and Listeria not only pose a serious threat to public health but also cause enormous losses to the global economy. In the process of building public health defenses, achieving rapid and accurate identification of high-risk pathogens has become crucial for ensuring food safety, and improving diagnostic efficiency.BacTrace&reg; Antibacterial AntibodySeraCare's KPL BacTrace&reg; series of antibacterial antibody product portfolio is an immunological reagent specifically developed for foodborne pathogens (Food Pathology) and bacterial infectious disease pathogens (Infectious Disease). It is primarily used in diagnostic reagent development and microbiological research. It covers key pathogenic bacteria that cause significant global economic losses, such as Salmonella, Listeria, Escherichia coli O157:H7, Helicobacter pylori, and Vibrio cholerae. Whether targeting bacterial surface antigens or intracellular antigens, this series provides high-specificity identification solutions. Thanks to its excellent performance, SeraCare KPL BacTrace&reg; antibodies have become a trusted choice for research and diagnosis in foodborne and infectious disease fields.Core Advantages of BacTrace&reg; Product SeriesUnique 'Dual-Effect' Production Process: Utilizing a proprietary immunization and purification strategy, it perfectly integrates the high capture efficiency of polyclonal antibodies with the high specificity similar to monoclonal antibodies, achieving stronger detection signals and lower background noise. This addresses the technical pain points of 'high background of traditional polyclonals and narrow coverage of monoclonals'.High Specificity (Low False Positives): Utilizes a proprietary affinity purification process. This removes non-specifically bound impurities, ensuring that the antibody reacts only with the target bacterial antigen, thereby significantly reducing false positive interference and enhancing the reliability of test results.High Sensitivity (Signal Amplification): Leveraging the ability of polyclonal antibodies to recognize multiple distinct epitopes on the same antigen. This significantly amplifies the detection signal, ensuring that even when the target concentration is extremely low, it can be accurately captured, achieving 'maximized detection'.Exceptional batch-to-batch consistency: Relying on KPL's strict QC processes, it ensures high consistency in antibody performance across different batches, avoiding experimental errors caused by reagent differences. This feature greatly simplifies the process validation for IVD and food safety test reagent manufacturers, helping products quickly pass registration approval.Broad-spectrum coverage and in-depth identification: It has the broad-spectrum reactivity across serogroups, covering a wider range of bacterial serogroups. It identifies the entire antigen spectrum from surface structures to intracellular components, ensuring comprehensive detection and effectively preventing missed detections.BacTrace&reg; Series Product ApplicationsIn Vitro Diagnostic Raw Materials: As core raw materials for IVD, they are used to produce immunological test strips or test kitsFood Safety Testing: Rapid Screening for the Presence of Specific Bacterial Antigens in SamplesMicrobiology Research: For the identification, classification, and study of pathogenic mechanisms of bacteriaPositive control: A quality control material in the laboratory to ensure the effectiveness of the detection systemSeraCare KPL BacTrace&reg; antibody supports multiple application formats including ELISA, WB, IHC, IF, and FC, and offers various labeling options such as unlabeled, HRP, AP, Biotin, and FITC to meet diverse experimental needs.BacTrace&reg; Series Partial Product List貨號英文品名中文品名規(guī)格5310-0337BACTRACE ANTI-B. BURGDORFERI伯氏疏螺旋體抗體1.0mg5330-0064FITC ANTI-B. BURGDORFERI伯氏疏螺旋體抗體 FITC標(biāo)記0.5mg5370-0023BACTRACE POS CTRL, B.BURGDORFERI伯氏疏螺旋體陽性對照1.0mL5310-0328BACTRACE ANTI-E. COLI O111大腸桿菌 O111抗體1.0mg5320-0036HRP-LABELED ANTI-E.COLI O111大腸桿菌 O111抗體 HRP標(biāo)記0.1mg5360-0033BIOTIN ANTI-E. COLI O111大腸桿菌 O111抗體 生物素標(biāo)記0.5mg5360-0033BIOTIN ANTI-E. COLI O111大腸桿菌 O111抗體 生物素標(biāo)記0.5mg5350-0037ANTI-E. COLI O157 MAG BEADS大腸桿菌 O157抗體磁珠1.0mL5370-0013BACTRACE POS CTRL, E.COLI O157:H7大腸桿菌O157:H7 陽性對照1.0mL5310-0326BACTRACE ANTI-E.COLI O157:H7大腸桿菌O157:H7抗體1.0mg5330-0062FITC ANTI-E.COLI O157:H7大腸桿菌O157:H7抗體 FITC標(biāo)記0.5mg5320-0035HRP-LABELED ANTI-E.COLI O157:H7大腸桿菌O157:H7抗體 HRP標(biāo)記0.1mg5360-0032BIOTIN ANTI-E.COLI O157:H7大腸桿菌O157:H7抗體 生物素標(biāo)記0.5mg5310-0327BACTRACE ANTI-E.COLI O157:H7, MOL GR大腸桿菌O157:H7抗體（分子級）1.0mg5310-0329BACTRACE ANTI-E. COLI O26大腸桿菌O26抗體1.0mg5360-0034BIOTIN ANTI-E. COLI O26大腸桿菌O26抗體 生物素標(biāo)記0.5mg5310-0314BACTRACE&reg; ANTI-S. AUREUS金黃色葡萄球菌抗體1.0mg5370-0007BACTRACE POS CTRL, S. AUREUS金黃色葡萄球菌陽性對照1.0mL5310-0319BACTRACE ANTI-LISTERIA GEN SPEC李斯特菌抗體1.0mg5360-0030BIOTIN ANTI-LISTERIA SPECIES李斯特菌抗體 生物素標(biāo)記0.5mg5310-0320BACTRACE ANTI-LISTERIA, HIGH SENS李斯特菌抗體（高特異性）1.0mg5370-0010BACTRACE POS CTRL, LISTERIA GENUS李斯特菌陽性對照1.0mL5310-0322BACTRACE ANTI-SALMONELLA CSA-1,沙門氏菌CSA-1抗體1.0mg5320-0044AP-LABELED ANTI-SALMONELLA CSA-1 沙門氏菌CSA-1抗體 AP標(biāo)記0.1mg5330-0059FITC ANTI-SALMONELLA CSA-1沙門氏菌CSA-1抗體 FITC標(biāo)記0.5mg5360-0031BIOTIN ANTI-SALMONELLA CSA-1沙門氏菌CSA-1抗體 生物素標(biāo)記0.5mg5310-0323BACTRACE ANTI-SALMONELLA CSA-1,ML GR沙門氏菌CSA-1抗體（分子級）1.0mg5350-0036ANTI-SALMONELLA CSA-1 MAG BEADS 沙門氏菌CSA-1抗體磁珠1.0mL5310-0321BACTRACE ANTI-SALMONELLA CSA-PLUS沙門氏菌CSA-Plus抗體1.0mg5370-0002BACTRACE POS CTRL, S. TYPHIMURIUM沙門氏菌陽性對照1.0mL5310-0325BACTRACE ANTI-HELICOBACTER PYLORI,幽門螺旋桿菌抗體1.0mg5320-0034HRP-LABELED GOAT ANTI-H. PYLORI,幽門螺旋桿菌抗體 HRP標(biāo)記0.1mg5370-0012BACTRACE POS CTRL, H.PYLORI,幽門螺旋桿菌陽性對照1.0mL5310-0310BACTRACE ANTI-SHIGELLA GEN SPEC 志賀氏菌抗體1.0mg5370-0003BACTRACE POS CTRL, SHIGELLA GENUS志賀氏菌陽性對照1.0mLKPL (Kinetic Plasmonics Laboratories) is a company with a deep history and excellent reputation in the field of biosciences. As one of the earliest biotechnology companies to commercialize affinity-purified secondary antibodies, KPL has laid a solid foundation for its development through its pioneering position in this area. Additionally, KPL is one of the world's largest producers of secondary antibodies and substrate color development systems, boasting nearly 40 years of product R&D experience and accumulating rich professional knowledge and technical strength. The company has obtained ISO13485 quality system certification, ensuring that all products have minimal batch-to-batch variation and reliable quality. KPL's products are characterized by high purity, high sensitivity, and high signal-to-noise ratio (strong signal, low background), and are trusted by researchers and diagnostic enterprises alike. In 2013, KPL was acquired by SeraCare, a supplier of in vitro diagnostic reagents, further consolidating its leading position in the industry. Founded in 1984, SeraCare is a major partner to global in vitro diagnostic manufacturers and clinical laboratories, and became part of the LGC Group in 2018.As the China general agent of LGC·Seracare·KPL brand, XMJ is committed to promoting KPL products in China, providing high-quality products and professional services to a wide range of scientific researchers. If you are interested in the products, please call Ximeijie's national customer service hotline at 400-050-4006 or visit the official website m.lxhmstone.com for more information. more>

A-172 (Arginine Glutamate): A Solution to Five Critical Challenges in High-Concentration Formulation Development

In the field of innovative drug development, particularly for high-concentration protein formulations, the solubility and long-term stability of the Active Pharmaceutical Ingredient (API) remain key bottlenecks determining drug development success. With the biopharmaceutical industry's growing demand for high-concentration formulations, the challenges of protein aggregation and precipitation under high-concentration conditions have become increasingly prominent. Pfanstiehl's newly launched novel pharmaceutical excipient, A-172 (Arginine Glutamate), is specifically designed to address these escalating formulation challenges in biologic drug development.A-172 is formed through ionic bonding between two natural amino acids found in the human body—arginine and glutamate—creating a structurally stable amino acid ion-pair salt. It effectively addresses common issues in high-concentration protein formulations, including low solubility, susceptibility to aggregation, and poor stability. Its zwitterionic properties enable effective interaction with protein surfaces, enhancing hydrogen bonding and electrostatic interactions while forming stable ion pairs. This significantly improves protein drug solubility and inhibits aggregation, thereby ensuring the stability of high-concentration formulations. Since its constituent amino acids are endogenous to the human body, A-172 demonstrates lower toxicity and superior biocompatibility, making it particularly suitable for subcutaneous injection formulations that require frequent administration and high patient compliance. Why A-172 (Arginine Glutamate) is an Excellent Excipient for Injectable Biologic Formulations: 1. Reducing Formulation Viscosity A-172 helps regulate the osmotic pressure of injectable solutions to physiological levels, improving the rheological properties of the drug solution, reducing viscosity, and enhancing flowability. This characteristic is particularly suitable for sensitive administration routes such as subcutaneous injection, reducing injection pain and tissue damage while improving the manufacturability of the formulation. 2. Enhancing Protein Solubility A-172 significantly improves the solubility of poorly soluble drugs in aqueous systems, ensuring effective drug release and bioavailability in vivo. It demonstrates excellent compatibility with peptides, proteins, antibodies, and small-molecule chemical drugs, providing an ideal dissolution environment for protein-based therapeutics. 3. Reducing Protein Aggregation By stabilizing protein structure, A-172 significantly reduces aggregation phenomena in high-concentration protein formulations, ensuring biologic drug activity and maintaining efficacy and safety during storage and administration. This is critical for preserving the quality stability of biologic formulations. 4. Minimizing Liquid-Liquid Phase Separation The natural buffering capacity of A-172 maintains stable pH in injectable solutions, preventing phase separation caused by pH drift. Its broad drug compatibility helps maintain formulation homogeneity, ensuring the product remains in a stable physical state throughout its storage period. 5. Improving Thermal Stability Through multiple stabilization mechanisms including inhibition of oxidation, aggregation, and pH drift, A-172 significantly enhances the physicochemical stability of injectable formulations, effectively extending product shelf life and providing reliable protection under various storage conditions. Pfanstiehl, maintaining its unwavering commitment to premium quality standards, is pleased to introduce injectable-grade L-Arginine L-Glutamate (A-172). This product delivers ultra-high purity, ultra-low endotoxin levels, and minimal metal ion content. Comprehensive quality testing covers DNA, RNA, DNase, RNase, phosphatase, protease, lipase, nitrite, mycoplasma, and additional critical parameters. A-172 is suitable for both biopharmaceutical and small-molecule drug manufacturing, with exceptional applicability for injectable formulation development. Product Features: Ultra-high purity, ultra-low endotoxin, and ultra-low microbial content Low metal impurity residue: 29 metal ions individually tested, all at ppb levels Tested for DNA, RNA, DNase, RNase, phosphatase, protease, lipase, and mycoplasma residues Tested for nitrite residues Tested for β-Glucans residues Manufactured in strict compliance with ICH-Q7 cGMP standards Multiple packaging specifications to support flexible applications from R&D to commercial production Product Applications: pH Buffering Agent Viscosity-Reducing Agent Stabilizer Solubility Enhancer Product Information: ProductName CASNumber ProductCode PharmacopoeiaCompliance DMF CDE CDE Status L-Arginine L-Glutamate,HighPurity,Low Endotoxin, Low Metals GMP 4320-30-3 A-172 Pfanstiehl sponsoring USP/NFmonograph 42345 F20250000567 I more>

Good's Buffer — MES

MES, the abbreviation for 2-(N-morpholino)ethanesulfonic acid, is a synthetic zwitterionic buffer. It was developed in 1966 by Norman Good and his team, belonging to the famous "Good's Buffers" family, and is one of the commonly used and important pH buffers in biochemical and molecular biology experiments.As a member of the "Good's Buffers" family, MES possesses a series of superior characteristics:① Ideal pKa value: The pKa of MES is 6.15 at 25°C. According to buffer theory, a buffer is most effective within ±1 pH unit of its pKa. Therefore, the ideal buffering range for MES is pH 5.5 - 6.7. This range covers the critical pH for many biochemical reactions.②Good biocompatibility: It causes minimal interference with enzyme activity and cell metabolism; has low cytotoxicity, making it commonly used in cell culture and protein studies.③Chemical inertness: Does not participate in or interfere with most biochemical reactions; does not strongly chelate essential divalent cations (such as Mg²?, Ca²?), which is crucial for the activity of many enzymes (e.g., ATP-related enzymes).④High water solubility: Highly soluble in water, allowing convenient preparation of high-concentration stock solutions (e.g., 1M).⑤Low UV absorption: Has very low absorbance at wavelengths above 260 nm, minimizing interference with UV spectrophotometric detection of nucleic acids or proteins.⑥Good thermal stability: Relatively stable at high temperatures.Given its superior physicochemical properties, MES offers significant advantages compared to other commonly used buffer components.MES vs. PBS (Phosphate Buffered Saline): PBS has strong buffering capacity in the pH 7.0-7.4 range but can chelate calcium and magnesium ions and may inhibit certain enzyme activities. MES does not have these issues and can work in more acidic pH conditions.MES vs. Tris: Tris has a pKa of 8.07 and is a classic buffer for the alkaline pH range. MES serves as a complement in the acidic to near-neutral range. Tris is temperature-sensitive and may participate as an active group in certain reactions.MES vs. HEPES: HEPES has a pKa of 7.55 and is one of the commonly used neutral buffers in cell culture. MES can serve as a complement to HEPES in more acidic pH ranges.Integrating the above advantages, MES finds wide application across various fields of life science research:? Protein Electrophoresis and Purification: SDS-PAGE / Chromatography.? Cell Biology: Used to prepare culture media or perfusion fluids to maintain pH stability in the extracellular environment.? Organelle Isolation: Provides a buffered environment in homogenization and centrifugation media for subcellular fractionation.? Biochemistry and Enzymology: Provides a stable pH environment for enzyme activity assays and enzyme kinetic studies.? Molecular Biology: Serves as a buffer component in Northern Blot and certain nucleic acid hybridization and detection experiments.In summary, MES is a high-performance, widely applicable buffer. Its core value lies in providing a stable, inert, and broadly compatible chemical environment within the weakly acidic physiological pH range of 5.5 - 6.7, ensuring the smooth progress of life science experiments.As a long-term, fixed supplier for many globally renowned culture media manufacturers and pharmaceutical companies, PanReac AppliChem provides reliable MES for researchers and pharmaceutical enterprises, leveraging its exceptional product quality and stringent quality control.ProductCodeChineseNameEnglishNameCASA06892-嗎啉乙磺酸MESanhydrous BioChemica4432-31-9 PanReac AppliChem is one of the high-quality manufacturers of biochemical reagents and pharmaceutical raw materials originating from Europe. With a century-long history, it has obtained multiple ISO quality management system certifications and serves as a key supplier to global life science research institutions, renowned CRO/CDMO companies, and large-scale industrial enterprises in the pharmaceutical, diagnostic, food, cosmetics, and other sectors.XMJ is the exclusive general distributor of PanReac AppliChem in China, providing users with comprehensive technical support and after-sales service. If you are interested in the products, please feel free to:· Call XMJ’s customer service hotline: 400-050-4006· Visit the official website: m.lxhmstone.com to learn more information. more>

New Product Recommendation | SISPROT? Proteomics Sample Preprocessing Kit

The sample preprocessing stage in proteomics experiments is a critical step to ensure the accuracy and consistency of experimental results. Given the complexity and numerous steps involved in the sample preprocessing workflow, developing an integrated and standardized experimental procedure is crucial for addressing the challenges in proteomics sample preprocessing. The SISPROT^®^ technology launched by BePepBio in 2023 is an integrated proteomics preprocessing technology based on the centrifugal pipette tip "Spintip". It enables one-stop completion of all steps in proteomics sample preprocessing from the crude sample, including protein sample pre-enrichment, reduction, alkylation, enzymatic digestion, and desalting. The processed samples can be directly used for LC-MS/MS analysis. This technology combines high sensitivity, high throughput, and high stability, making it particularly suitable for protein samples in the low microgram or even nanogram range.Product FeaturesHigh Efficiency: Complete sample processing within 2 hoursWhile traditional methods require 16 hours, the SISPROT Kit completes all sample preprocessing steps within 2 hours, and the processed samples are ready for direct instrumental analysis.High Sensitivity: Approximately 6000 proteins detected from 100ng Approximately 6000 proteins can be stably detected from 100ng. The minimum initial sample amount can be as low as 1ng (equivalent to ~10 cells).High Stability: Excellent quantitative reproducibility across different operatorsPopular ProductsSISPROT® SEStably identifies 7000+ proteins starting from just 500ng of protein, addressing the difficulty in detecting low-abundance proteins. Features simple operation and excellent reproducibility. Suitable for proteomics sample preprocessing of blood, body fluids, cells, exosomes, and other samples. Applicable in large-scale population cohort studies using blood samples and disease molecular subtyping research, high-throughput screening for drug targets, spatial proteomics, and other fields.SISPROT® Flex  Requires only 1-10μg of protein per operation for conventional samples, saving sample consumption. Compatible with SDS lysis buffer. Suitable for plant tissue, animal tissue, cells, plasma, serum, saliva, urine, cerebrospinal fluid, protein solutions, and other samples. Applicable in medical research fields such as biological mechanism exploration, diagnostic technology development, and therapeutic strategy research.Product InformationProduct NameCatalog No.SpecificationSISPROT® SE BO-008-9696T/KitBO-008-2424T/ KitBO-008-066T/ KitSISPROT® FLEX BO-012-2424T/ KitBO-012-066T/ KitRelated Literature ? Simple and integrated spintip-based technology applied for deep proteome profiling, Anal. Chem., 2016, 88(9):4864-71. ? 3D-SISPROT: A simple and integrated spintip-based protein digestion and three-dimensional peptide fractionation technology for deep proteome profiling, J. Chromatogr. A, 2017, 1498:207-214. ? Mixed-mode ion exchange-based integrated proteomics technology for fast and deep plasma proteome profiling, J. Chromatogr. A, 2018, 1564:76-84.Shenzhen Baymics Biotechnology Co., Ltd. is an R&D-focused high-tech company specializing in proteomics. Starting with its series of proteomics preprocessing products, the company aims to provide comprehensive workflow solutions for the target market through its clinical functional proteomics technology platform. The company is dedicated to reducing the technical complexity of proteomics analysis and enhancing its application throughout the entire chain of innovative biomarker and drug discovery, providing precise diagnosis and treatment strategies for major diseases using proteomics technology. As the exclusive China distributor for BePepBio, Beijing Ximeijie Technology Co., Ltd. has established long-term and stable partnerships with numerous well-known domestic pharmaceutical companies and CRO/CMO enterprises. Over the years, Ximeijie's products and services have helped many companies accelerate their R&D stages, improve drug quality, purity, and safety, optimize R&D processes, shorten time-to-market, and reduce QC costs. If you are interested in the aforementioned products, please call the Ximeijie customer service hotline at 400-050-4006 or visit the website m.lxhmstone.com for more information. more>

Mirus Universal Transfection Reagent: TransIT-X2? for Multiple Nucleic Acid/Protein and Cell Types

Based on research needs for delivering different types of nucleic acids/proteins, researchers often encounter the following three types of problems during cell transfection: · Cells are relatively sensitive to chemical reagents, leading to decreased cell viability or cell death after transfection; · A large variety of cell types are commonly used in research, and transfection efficiency varies significantly among different cell types. As a result, a single transfection reagent or experimental protocol cannot meet the experimental requirements; · Delivering multiple types of nucleic acids or proteins requires selecting corresponding transfection reagents and conducting extensive experimental optimization to achieve high transfection efficiency. Is there a chemical transfection reagent that can handle both conventional and hard-to-transfect cell types, has low cytotoxicity, and is suitable for delivering multiple types of nucleic acids/proteins? The TransIT-X2® Transfection Reagent, which combines multiple functions and high performance, can handle both common and hard-to-transfect cell types simultaneously. It eliminates the need for condition exploration and extensive repetitive experiments, allowing you to easily obtain your desired experimental results. · It has been verified to exhibit excellent transfection efficiency, low cytotoxicity (especially compared to Lipofectamine® series reagents that form liposome complexes), and high performance in most cell types (such as adherent/suspension cells, primary cells, and neural cells); · It is suitable for a wide range of research fields, including but not limited to stem cell research, CRISPR-based gene editing research, RNAi gene interference/silencing, stable cell line generation, low-toxicity transfection experiments, and co-transfection experiments; · It enables efficient and stable simultaneous delivery of multiple types of nucleic acids/proteins, including but not limited to plasmid DNA, siRNA/miRNA, and CRISPR/Cas9 components. Why does the Mirus TransIT-X2® Dynamic Delivery System possess such high performance and broad adaptability? This is attributed to Mirus’ powerful and efficient patented delivery platform design, which enables screening and optimization of transfection reagent components for multiple and multifunctional combinations. Founded in 1995, Mirus has focused on and specialized in the field of nucleic acid delivery for many years (Figure 1). From the earliest low-toxicity TransIT®-LT1 to the GMP-grade TransIT-VirusGEN® (which can be used for AAV and LV production), all products are designed and developed based on this delivery platform. To date, more than 10,000 research papers have been published using Mirus products, and these papers and Mirus’ database cover over 1,200 cell types. For more papers and data queries, please click here. Figure 1 Mirus Product Milestones Unlike traditional single-component-based transfection reagents (such as cationic polymers or cationic liposomes), Mirus combines its patented polymer and lipid technologies in multiple ways to further improve transfection efficiency for addressing different cell types or specific applications. Without forming liposomal complexes (i.e., liposomes, which usually have cytotoxicity), this multi-combination approach yields a variety of high-performance transfection solutions. These solutions overcome multiple obstacles in the cell delivery process, enabling more efficient transfection and lower cytotoxicity (Figure 2). Figure 2 Schematic Diagram of the Principle of Mirus Transfection Reagents Based on the design of Mirus' powerful and efficient patented delivery platform mentioned above, combined with its unique intelligent iterative design process— which involves multi-component, multi-combination screening, optimization, and subsequent validation—each component in the transfection technology is optimized (Figure 3). Mirus has launched a series of classic transfection reagents to meet diverse needs: 1. Broad-Spectrum, High-Performance, Low-Toxicity Transfection Reagent Family: TransIT-X2®, TransIT®-LT1, TransIT®-2020 2. Transfection Reagent Family for Specific Cell Types: TransIT®-293, TransIT®-BrCa, TransIT®-CHO, TransIT-HeLaMONSTER®, TransIT®-Insect, TransIT®-Jurkat, TransIT®-Keratinocyte 3. Transfection Reagent Family for Specific Applications: · Viral Production: VirusGEN® Transfection Reagents and Matching Kits, TransIT®-Lenti · Protein/Antibody Production: TransIT-PRO®, CHOgro® Expression System, CHOgro® High Yield Expression System 4. Transfection Reagent Family for Oligonucleotide Delivery: TransIT®-Oligo, TransIT-siQUEST®, TransIT-TKO® 5. mRNA and Long-Chain RNA Delivery: TransIT®-mRNA Figure 3 Schematic Diagram of Mirus' Unique Intelligent Iterative Design for Transfection Reagent Optimization Process Performance Data Presentation of Mirus TransIT-X2® Transfection Reagent Figure 4 TransIT-X2® Exhibits High Transfection Efficiency in Multiple Cell Types, Including Primary CellsThe Mirus TransIT-X2® Dynamic Delivery System was used to deliver and express EGFP plasmid DNA into A549, CHO-K1, Hep G2, MDCK, LNCaP, PC-12, primary human mammary epithelial cells (HMEC), and normal human dermal fibroblasts (NHDF) respectively.The experiment was conducted in 96-well plates, with the TransIT-X2® reagent added at a volume of 0.2-0.4 µl and DNA added at 0.1 µg (using reagent:DNA ratios of 2:1, 3:1, or 4:1). At 48 hours post-transfection, transfection efficiency was evaluated through three repeated detections using a Guava® easyCyte? 5HT flow cytometer. Luciferase-encoding plasmid DNA was transfected into A549 (A) or MDCK (B) cells using TransIT-X2® (Mirus Bio), Lipofectamine®2000 (Thermo Fisher Scientific), or Lipofectamine®3000 (Thermo Fisher Scientific). At 24 hours post-transfection, transfection efficiency was evaluated by luciferase activity, and cytotoxicity was assessed by quantifying LDH released from damaged cells. Compared with cells treated with Lipofectamine®2000 or Lipofectamine®3000, TransIT-X2® exhibited higher fluorescence intensity and lower cytotoxicity at the optimal reagent:DNA ratio. Figure 5 Compared with Lipofectamine® series transfection reagents (which are single-component and form cationic liposomal complexes), TransIT-X2® shows higher transfection efficiency and lower cytotoxicity Experimental Tips: For more specific cell types and recommendations on reagent usage, please refer to the details in：Cell-type specific transfection protocol recommendations (PDF). Performance Data Presentation of Mirus TransIT-X2® in RNAi Experiments Functional research related to gene silencing plays a crucial role in molecular and cellular biology, and chemical transfection also plays an important part in this research field. Common natural RNA molecules involved in the RNAi pathway include: · Small interfering RNAs (siRNAs): Short double-stranded RNAs (20-25 bp) generated by the cleavage of double-stranded RNA (dsRNA); · MicroRNAs (miRNAs): A class of short, single-stranded RNAs (20-22 nt) produced after the processing of non-coding RNAs. Another method for inhibiting gene expression using RNAi is short hairpin RNA (shRNA). These short RNA sequences can be expressed via viral or non-viral vector methods. For more detailed information, please refer to Mirus  Applications | RNAi Gene Silencing。 Figure 6 Schematic Diagram of Different RNAi Pathways Figure 7 In gene silencing studies based on siRNA nucleic acid delivery, TransIT-X2® exhibits higher gene silencing efficiency compared to Lipofectamine®2000The TransIT-X2® Dynamic Delivery System and Lipofectamine®2000 transfection reagents were used to transfect siRNAs (targeting endogenous proteins—GAPDH and AHA1). For the control group, normal human dermal fibroblasts (NHDF) were used to deliver non-targeting siRNA. The amount of TransIT-X2® added was 4 µl, the amount of Lipofectamine®2000 added was 6 µl, and the amount of siRNA added was 25 nM for both reagents. qRT-PCR was performed to measure the mRNA levels of GAPDH or AHA1 relative to 18s rRNA. At 48 hours post-transfection, the mRNA levels were normalized to those of the non-targeting control group. The error represents the standard deviation from three replicate well experiments. Figure 8 In gene silencing studies based on miRNAs (miRNA Precursor and miRNA mimic), TransIT-X2® exhibits higher gene silencing efficiency compared to Lipofectamine®2000The TransIT-X2® Dynamic Delivery System and Lipofectamine®2000 transfection reagents were used to transfect Pre-miR? hsa-miR-1 miRNA Precursor or mirVana? miRNA mimic, miR-1 (both have been validated to reduce PTK9 mRNA expression levels). Pre-miR? negative control was used to assess the baseline level of mRNA expression. The amount of both TransIT-X2® and Lipofectamine®2000 reagents added was 3 µl, with 50 nM miRNA added. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure PTK9 mRNA expression levels relative to 18s rRNA, and the results were normalized against the negative control. Performance Data of Mirus TransIT-X2® in CRISPR Gene Editing Experiments The modified and optimized bacterial CRISPR/Cas9 system has been widely applied in gene editing of mammalian cells. There are two common key components in CRISPR-based gene editing experiments: Cas9 protein and guide RNA (gRNA). When Cas9 protein cleaves the target genomic DNA, it triggers two endogenous repair mechanisms, namely non-homologous end joining (NHEJ) and homology-directed repair (HDR), to address DNA breaks formed in cells. The NHEJ-based cellular repair pathway is an imprecise and error-prone repair mechanism, which can introduce indels (insertions or deletions) that lead to loss of gene function. In contrast, the HDR-based cellular repair pathway requires additional homologous DNA as a repair template to achieve "precision" repair, allowing the insertion of specific genes or long-fragment sequences into the target gene. According to researchers' different experimental needs, CRISPR gene editing can be set up in multiple experimental configurations. This means addressing the transfection or even co-transfection of different nucleic acid types, with examples as follows: 1. Plasmid pDNA Transfection The two key components of a CRISPR experiment—Cas9 protein and gRNA—can be designed to be co-expressed in a single plasmid DNA (A); alternatively, a two-plasmid system can be used, where one plasmid expresses Cas9 protein and the other expresses gRNA (B); when a Cas9 nickase is used, two gRNAs are required, which may necessitate a three-plasmid system for delivery experiments. 2. Co-transfection of Plasmid DNA and RNA Oligonucleotides In this case, different from the above experimental design, gRNA is delivered in the form of oligonucleotides, which means the delivery experiment requires simultaneous transfection of plasmid DNA and RNA oligonucleotides (A and B). 3. Co-transfection of mRNA and RNA Oligonucleotides To avoid off-target effects caused by genomic integration of plasmid DNA, mRNA encoding Cas9 protein and gRNA (RNA oligonucleotides) can be co-transfected. 3. Delivery of Cas9/gRNA RNP Complexes As the commercialization of Cas9 protein and gRNA becomes increasingly mature, more and more researchers choose to directly purchase high-fidelity Cas9 protein and gRNA oligonucleotides with additional chemical modifications (which enhance their stability in cells) from third-party suppliers. Apart from greatly shortening and simplifying the CRISPR experimental workflow, the direct delivery of RNP complexes offers higher specificity and editing efficiency compared to the approaches that rely on plasmid- or mRNA-based synthesis of Cas9 and gRNA. Experimental Tips: For the specific experimental instructions optimized for the TransIT-X2® Dynamic Delivery System (tailored to the different CRISPR experimental designs and delivery scenarios mentioned above), the download link is as follows: TransIT-X2® for CRISPR Plasmid + gRNA Delivery (PDF) TransIT-X2® for CRISPR Plasmid Delivery (PDF) TransIT-X2® for CRISPR RNP + ssODN Delivery (PDF) TransIT-X2® for CRISPR RNP Delivery (PDF) The TransIT-X2® Dynamic Delivery System (2 µl/well in 24-well plates, Mirus Bio) was used to co-transfect 0.5 µg of plasmid DNA (expressing Cas9 protein) and 50 nM of 2-part gRNA (targeting the PPIB gene) into HEK293T/17, U2OS, and NHDF cells. At 48 hours post-transfection, T7E1 assay was performed to verify the cleavage efficiency. Figure 9 Co-transfection of Plasmid DNA and gRNA Oligonucleotides: TransIT-X2® achieved high gene editing efficiency (18-48%) when co-transfecting Cas9 plasmid DNA and gRNA (RNA oligonucleotides) into 293T/17, U2OS, and NHDF cells, respectively The 2-part gRNA (targeting PPIB gene, IDT) and Cas9 protein (PNA Bio) formed RNP complexes, which were respectively delivered into 293T/17 and U2OS cells using TransIT-X2® Dynamic Delivery System (1 µl/well, Mirus Bio), Lipofectamine® CRISPRMAX? (1.5 µl/well, ThermoFisher), Lipofectamine® RNAiMAX (1.5 µl/well, ThermoFisher), and Lipofectamine® 3000 (1.5 µl/well, ThermoFisher). Two usage amounts of gRNA were tested (6 nM or 12 nM) with the same amount of Cas9 protein added (6 nM). At 48 hours post-transfection, the T7E1 assay was performed to verify the cleavage efficiency. Figure 10 Delivery of Cas9/gRNA RNP Complexes: TransIT-X2® exhibits higher cleavage efficiency compared to Lipofectamine® series transfection reagents Advantages of Mirus TransIT-X2® Product ? A new broad-spectrum transfection reagent developed based on multiple components (suitable for various cells, including hard-to-transfect cells); ? Capable of co-transfecting nucleic acids and proteins, including but not limited to DNA, siRNA/miRNA, and CRISPR/Cas9 complexes; ? Does not form liposomal complexes, reducing cytotoxicity; ? Meets multiple applications: gene overexpression, gene silencing, gene editing, stem cell research, stable cell line construction, etc.Related Product Information Product Name SpecificationItem Number TransIT-X2® Dynamic Delivery System 1 × 0.3 ml MIR 6003 1 × 0.75 ml MIR 6004 1 × 1.5 ml MIR 6000 5 × 1.5 ml MIR 6005 10 × 1.5 ml MIR 6006 End-of-Article Benefit: Follow Ximeijie's official WeChat public account "xmjsci", reply with the keyword "X2 Trial", and fill in the information to have the opportunity to receive a free 100μl trial sample of TransIT-X2® Transfection Reagent. After a successful trial, you can also enjoy a discount when purchasing the full-size TransIT-X2®! Come and apply for the trial and make your purchase now! Founded in 1995, Mirus (USA) is one of the earliest companies in the world to develop high-efficiency and low-toxicity transfection reagents, and also one of the leading suppliers of such reagents currently. Recognized as a pioneer in transfection reagent development, Mirus has achieved numerous outstanding results that have gained global recognition and high praise from a wide range of users.Beijing XMJ Technology Co., Ltd. is the authorized distributor of Mirus in China. Adhering to a professional and rigorous attitude, we have been committed to providing customers with high-quality products and services. If you are interested in the aforementioned products, please feel free to send email to info@xmjsci.com or visit the official website m.lxhmstone.com to obtain more product information. more>

Cygnus CHO 6xLipase? MS Assay——Accurately Quantifying Risks, Clarifying Process Optimization Directions

In biopharmaceutical production, host cell protein (HCP) residuals are one of the key factors affecting drug stability. Among them, lipase-class HCPs are a major focus within HCP residuals due to their potential to degrade surfactants commonly used in formulations (such as Tween-80/20). Tween degradation leads to an increase in free fatty acids in the drug solution, which can induce protein aggregation, formation of fatty acid-protein complex particles, and subsequently impact product safety and efficacy. While the ELISA HCP detection method can assess overall HCP levels, it cannot identify specific types of lipases, making it difficult to precisely evaluate process-related risks. To address this issue, Cygnus Technologies has developed a targeted proteomics analysis method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) – the CHO 6xLipase? MS Assay. This method utilizes Parallel Reaction Monitoring (PRM) technology and Stable Isotope-Labeled peptides (SIL) to achieve absolute quantification of six CHO-derived HCP lipases known to cause Tween degradation:： HCP LOD (ppm) Quantification Range (ppm) Lysosomal Acid Lipase（LAL） 0.15 18.25 - 292.06 Lipoprotein Lipase（LPL） 0.08 0.10 - 323.34 Phospholipase A1（PLA1） 0.12 0.49 - 311.67 Group XV Lysosomal Phospholipase（GXVPA2） 0.03 4.72 - 302.31 Phospholipase B-Like 2（PLBL2） 0.56 0.66 - 419.46 Phosphoinositide Phospholipase C（PIPLC） 0.09 13.91 - 890.07 Technical RoadmapTechnical Advantages: ? Pharmacopeial Method: PRM combined with SIL peptides is an absolute quantification method recognized by the USP <1132.1> guideline, with accuracy and precision far exceeding semi-quantitative methods. ? Excellent Linear Range: All 6 lipases show R² ≥ 0.98, with a quantification range covering 0.1 - 890 ppm, meeting detection needs from early process stages to final product. ? Stringent Validation Standards: Accuracy error <35%, precision %CV <25%, Limit of Detection (LOD) as low as 0.03 - 0.56 ppm. Case Studies Client 1: High-Risk Sample (DS-top): Fc-Fusion Protein ? Tween20 degradation (complete degradation within 3 months) ? 5 lipases detected, multiple enzymes synergistically accelerating Tween degradation HCP Predicted Concentration (ng/mL) %CV GXVP_A2 1.15 5.2% LAL 2.76 9.6% LPL 6.94 2.3% PIPL_C NA PL_A1 0.23 3,2% PLBL2 12.4 Client 2: Stable Sample (DS-bottom): Monoclonal Antibody ? Tween20 degradation detected ? Only PLBL2 detected (3.06 ng/mL), the other 5 were below the limit of detection HCP Predicted Concentration (ng/mL) %CV GXVP_A2 NA LAL NA LPL NA PIPL_C NA PL_A1 NA PLBL2 3.06 3.20% Service Package: Standard Service Cycle: Approximately 6 weeks (from sample receipt to report issuance) Expedited Service: 4-week or 2-week options available (additional fees apply) Sample Requirement: 1 mL of DS sample quantified by BCA assay (concentration ≥ 4 mg/ml) If you are interested in our lipase residual detection service, please click here to fill out the form. XMJ will contact you promptly to share more detailed information. Cygnus Technologies, LLC. provides products and analytical methods for the biotechnology and biopharmaceutical industry, aiming to accelerate R&D stages and improve product quality. Cygnus develops and manufactures bioprocess residual kits for detecting specific impurities across over 50 different expression systems. As an expert in highly sensitive analytical techniques for biotechnology applications, particularly immunoassays, Cygnus's products and services have been used by nearly all major biopharmaceutical companies for over 25 years. Beijing XMJ Science & Technology Co., Ltd., as the exclusive distributor of Cygnus in China, has established long-term and stable cooperative relationships with numerous renowned domestic pharmaceutical companies and CRO/CMO enterprises. Over the years, XMJ's products and services have helped many companies accelerate R&D stages, improve drug quality, purity, and safety, optimize R&D processes faster, reduce time-to-market, and lower QC costs. If you are interested in the above products, please feel free to contact XMJ customer service hotline at 400-050-4006 or visit the website m.lxhmstone.com for more information. more>

【Strategic Cooperation】XMJ Joins Hands with Synthego to Bring Advanced CRISPR Technology Solutions

CRISPR, an acronym for "Clustered Regularly Interspaced Short Palindromic Repeats," refers to an adaptive immune mechanism found in bacteria and archaea. This system comprises Cas nucleases and guide RNAs (gRNAs) and was initially utilized by microorganisms to recognize and cleave viral DNA, thereby providing immunity against viral infections. It has since been engineered into a powerful gene-editing tool. Following the seminal discovery by Drs. Doudna and Charpentier in 2012 of the molecular mechanism underlying DNA cleavage mediated by the CRISPR-Cas9 system, extensive research and optimization efforts by the global scientific community have advanced this technology into a highly precise and broadly applicable genomic editing platform. Currently, CRISPR-based technologies are widely employed across diverse fields, including gene editing, RNA editing, base editing, molecular diagnostics, and live-cell imaging. They have enabled genetic modifications in a wide range of organisms, including humans, thereby accelerating advancements in both basic research and clinical applications. To achieve precise gene editing using CRISPR technology, the design of guide RNA (gRNA) and the selection of Cas nucleases are two critical factors. The choice of gRNA depends primarily on the specific type of genetic modification required, such as gene knockout (KO), gene knock-in (KI), base editing, prime editing, CRISPR interference (CRISPRi), or CRISPR activation (CRISPRa). Synthego offers a freely accessible CRISPR design tool available to researchers worldwide, which facilitates the design and selection of optimal gRNA sequences for targeted editing of over 120,000 genes. Furthermore, the appropriate selection of Cas enzymes is essential for experimental success. Cas9, originally derived from Streptococcus pyogenes (SpCas9), was the first widely adopted nuclease and remains the most commonly used. However, a growing range of natural and engineered Cas variants are now available for specialized applications. For example, Cas9 nickase induces single-strand breaks to enhance editing precision, while high-fidelity Cas9 variants significantly reduce off-target effects. Additionally, Cas13, a naturally occurring nuclease, demonstrates considerable potential in molecular diagnostics. In advancing the application and development of CRISPR technology, Synthego serves not only as a leading provider of integrated CRISPR solutions but also as a strategic partner committed to innovation and customer success. The company supplies all key components required for CRISPR-based gene editing, including gRNA design and synthesis services, as well as a comprehensive portfolio of natural and engineered gene editing enzymes. Its product offerings span research-grade, clinical-grade, and GMP-grade materials, supporting researchers throughout the entire pipeline—from basic research to clinical translation. Research-grade product for preclinical research and development Within Synthego's product portfolio, research-grade products hold a central position, specifically developed to support early-stage preclinical research. Notably, these products are manufactured under the same rigorous quality control standards as GMP-grade materials, ensuring high reliability and reproducibility of experimental outcomes. Synthego's research-grade gRNAs have been widely adopted by leading academic institutions, biotechnology firms, and pharmaceutical R&D organizations globally, and are recognized as an industry benchmark in CRISPR-based reagent synthesis. This positions Synthego as one of the few companies capable of delivering research tools that meet clinical-level standards of rigor. The INDe solution helps optimize the early clinical stage Establishing a robust bridge between early preclinical research and regulatory compliance remains one of the most significant challenges in the development of CRISPR-based therapies. This transitional phase often acts as a critical bottleneck, potentially resulting in project delays or developmental stagnation. Synthego's INDe solution is specifically designed to address this pivotal stage by providing cost-effective, moderately scalable, quality-controlled, and customizable options tailored to the demands of preclinical optimization. Synthego's INDe gRNAs enable researchers to validate candidate therapeutics, refine editing processes, and establish a solid foundation for clinical-scale manufacturing. Synthego INDe solutions "GMP-like" processes INDe solutions are invaluable for validating therapeutic targets under conditions that closely mimic GMP standards. INDe gRNAs include documentation like batch records, traceability, and validation to support your IND submissions and early-phase trials, while helping you avoid the expense of full GMP until you truly need it, so you can maximize your budget across development milestones. By using INDe, you gain insights that will smooth the transition into GMP-grade production, cutting down time and costs associated with re-validation. The reliance on "GMP-like" processes has become widespread for producing materials intended for IND-enabling studies and clinical use. Yet, "GMP-like" processes often lack the documentation, quality oversight, and comprehensive controls required to meet the demands of regulatory submissions. They frequently result in variability and insufficient traceability, which can delay regulatory approvals, and hinder the safety and efficacy of therapeutic products. GMP-Grade Products for Clinical Trials Synthego’s GMP-grade gRNAs and nucleases set the benchmark for quality, reliability, and compliance in CRISPR clinical manufacturing. Developed under strict Good Manufacturing Practice (GMP) guidelines, these products are tailor-made to meet the precise standards required for IND submissions and therapeutic-grade applications. With Synthego as your partner, you’ll benefit from cutting-edge manufacturing capabilities coupled with the assurance of meeting even the most demanding regulatory requirements. Having supported over 12 IND submissions for CRISPR therapies, Synthego has become a trusted name in the industry. Leaders continue to rely on us not just for our products, but for the assurance that their work is built on a foundation of excellence. Our GMP offering stands as a testament to our commitment to revolutionize the field of gene editing with therapeutic outcomes in mind. Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale. XMJ Scientific is the distributor of Synthego in China, providing users with comprehensive technical support and after-sales service. Welcome to call XMJ's customer service hotline at 400-050-4006 or visit the website m.lxhmstone.com for more information at any time. more>

About Us

Introduction

Beijing XMJ Technology Co., Ltd., founded in 2005, is a supplier of reagent raw materials and auxiliary materials focusing on the fields of life sciences, biopharmaceuticals and related areas. It is committed to providing comprehensive product solutions and technical support services for scientific research institutions more>

Represented Brands